BoneGrafix

BoneGrafix

Bonegrafix products contain bioactive substances to produce ideal graft attributes. These products fall into two categories: (1) solid bone blocks for bone replacement and (2) small powdered or granular substances (with and without inclusion of a cement) for filling defects or holes in bone or stabilizing bone during the healing process.

Bonegrafix is developing bone blocks in standard shapes (e.g., cube, rectangle, or wedge) as well as custom sizes capable of shaping and manipulation by a clinician. Using information obtained from a patient’s anatomical CT scan, clinicians will be able to select the precise skeletal area where bone addition and/or replacement is required. Bonegrafix can produce a precise bone replacement with optimal surface contact area for maximum tissue regeneration.

In a series of proof-of-concept studies, Bonegrafix has demonstrated production of a bone replacement based on CT data as well as a custom design using computer-aided-design (CAD). This feature would be especially important for plastic or maxillofacial surgeons performing craniofacial reconstruction.

Additional studies indicate significant advantages to Bonegrafix technology, most notably, more rapid new bone formation with greater volume when compared to available options.

Unique to Bonegrafix technology is ambient room temperature processing. As the Company’s manufacturing process does not degrade heat sensitive biologics and/or drugs, it permits direct inclusion to promote rapid bone healing and new bone formation.

Find out more about BoneGrafix »

Who we are

About
Biomimix

Biomimix, Inc. is commercializing products and technologies based upon biomimicry – modeling nature’s processes, systems and elements to solve complex problems and address large unmet medical needs. The Company will invest in high-potential product development, licensing and joint venture partnerships to advance products to market. Biomimix is focused on medical device applications, drug development programs including OTC products, and targeted platform technologies serving niche indications which present high commercial potential. The Company will acquire marketed products and services where Biomimix can leverage sales and marketing and distribution channel expertise to drive revenue growth.

Read More »

Press Releases

No releases found at the moment

Contact Us

Telephone 703-889-8332
44081 Pipeline Plaza, Suite 320
Ashburn, VA 20147
USA

Investor Relations

Rob Karbowsky

44081 Pipeline Plaza, Suite 320
Ashburn, VA 20147

Telephone +1 407 614 5953
TelephoneToll Free: +1 866 960 6687
Email rob@k2pr.net